RBC Capital today maintained an Outperform rating on ARIAD Pharmaceuticals (NASDAQ: ARIA) with a price target of $36.00. Analyst Michael ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE